CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma

Dental Research Journal

Volumn 12, Issue 2, 2015, Pages 181-186

  Shakib, Pouyan ^a,b   Ensani, Fereshteh ^b   Abdirad, Afshin ^b   Valizadeh, Bahareh ^a   Seyedmajidi, Maryam ^a   Sum, Shima ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antigen; carcinoma; CD24; CD44; immunohistochemistry; squamous cell of head and neck

Indexed keywords

EID: 84954359608     PISSN: 17353327     EISSN: 20080255     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lohavanichbutr P, Houck J, Doody DR, Wang P, Mendez E, Futran N, et al. Gene expression in uninvolved oral mucosa of OSCC patients facilitates identification of markers predictive of OSCC outcomes. PLoS One 2012;7:e46575.
2. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol 2007;43:523-34.
3. Regezi JA, Sciubba JJ, Jordan RC. Oral Pathology; Clinical Pathologic Correlations. 5 th ed. Missouri: Saunders; 2008. p. 48-52.
4. Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR. The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 2004;26:660-74.
5. Zanaruddin SN, Saleh A, Yang YH, Hamid S, Mustafa WM, Khairul Bariah AA, et al. Four-protein signature accurately predicts lymph node metastasis and survival in oral squamous cell carcinoma. Hum Pathol 2013;44:417-26.
6. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-95.
7. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin Dev Immunol 2012;2012:708036.
8. de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013;66:187-91.
9. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255-62.
10. Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res 2012;72:5600-12.
11. Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, et al. CD24 controls Src/STAT3 activity in human tumors. Cell Mol Life Sci 2012;69:3863-79.
12. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-7.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.
14. Zhang Z, Filho MS, Nör JE. The biology of head and neck cancer stem cells. Oral Oncol 2012;48:1-9.
15. Rastogi P. Emergence of cancer stem cells in head and neck squamous cell carcinoma: A therapeutic insight with literature review. Dent Res J (Isfahan) 2012;9:239-44.
16. Sayed SI, Dwivedi RC, Katna R, Garg A, Pathak KA, Nutting CM, et al. Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol 2011;47:237-43.
17. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011;278:1429-43.
18. Wei W, Hu H, Tan H, Chow LW, Yip AY, Loo WT. Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis. J Transl Med 2012;10 Suppl 1:S6.
19. Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, Lee CC. CD44/CD24 expression in recurrent gastric cancer: A retrospective analysis. BMC Gastroenterol 2012;12:95.
20. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
21. Barrera CA, Beswick EJ, Sierra JC, Bland D, Espejo R, Mifflin R, et al. Polarized expression of CD74 by gastric epithelial cells. J Histochem Cytochem 2005;53:1481-9.
22. Moller P, Henne C, Moldenhauer G. CD74 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V, White Cell Differentiation Antigens. Vol. 1. New York: Oxford University Press, Inc.; 1995. p. 568-71.
23. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, et al. CD74: A new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556S-63.
24. Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15:2855-61.
25. Duivenvoorden WC, Beatty LK, Lhotak S, Hill B, Mak I, Paulin G, et al. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer 2013;108:327-33.
26. Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546-50.
27. Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013; 12:968-78.
28. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and Maxillofacial Pathology. 3 rd ed. Missouri: Saunders; 2009. p. 419.
29. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med 1989;18:432-7.
30. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 2009;1:27.
31. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: A retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol 2010;5:649-57.
32. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013;85:1219-26.
33. Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, et al. Complications of targeted drug therapies for solid malignancies: Manifestations and mechanisms. AJR Am J Roentgenol 2013;200:475-83.
34. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008;30:800-9.
35. Caponigro F, Milano A, Basile M, Ionna F, Iaffaioli RV. Recent advances in head and neck cancer therapy: The role of new cytotoxic and molecular-targeted agents. Curr Opin Oncol 2006;18:247-52.
36. Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumour Biol 2012;33:707-21.
37. Ji SQ, Su XL, Cheng WL, Zhang HJ, Zhao YQ, Han ZX. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway. Urol Oncol 2014;32:153-61.
38. Oliveira LR, Oliveira-Costa JP, Araujo IM, Soave DF, Zanetti JS, Soares FA, et al. Cancer stem cell immunophenotypes in oral squamous cell carcinoma. J Oral Pathol Med 2011;40:135-42.
39. Faber A, Barth C, Hörmann K, Kassner S, Schultz JD, Sommer U, et al. CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep 2011;26:321-6.